| Menopause |
1 |
0.59 |
| Progestin |
0 |
0.55 |
| Contraception |
0 |
0.54 |
| Pain Management |
0 |
0.53 |
| Estrogen |
0 |
0.51 |
| Pelvic Pain |
0 |
0.45 |
| Endometriosis |
0 |
0.37 |
| Pain |
0 |
0.34 |
| Testosterone |
0 |
0.25 |
| Postmenopause |
0 |
0.17 |
| Skin and Soft Tissue Infection |
0 |
0.14 |
| Anovulation |
0 |
0.13 |
| Hormonal Therapy |
0 |
0.13 |
| Match |
0 |
0.13 |
| Polycystic Ovary Syndrome |
0 |
0.12 |
| Dysfunctional Uterine Bleeding |
0 |
0.09 |
| Acne |
0 |
0.08 |
| Biopsy |
0 |
0.08 |
| Complementary and Alternative Medicine |
0 |
0.08 |
| Hair |
0 |
0.08 |
| Infertility Female |
0 |
0.08 |
| Insurance |
0 |
0.08 |
| Laparoscopy |
0 |
0.08 |
| Ovary |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.08 |
| Uterus |
0 |
0.08 |
| Weight Gain |
0 |
0.08 |
| Weight Management |
0 |
0.08 |
| Gonadotropin-Releasing Hormone (GnRH) Antagonist |
0 |
0.06 |
| Pelvic Ultrasonography |
0 |
0.06 |
| Adherence |
0 |
0.04 |
| Adverse Effects |
0 |
0.04 |
| Bruise |
0 |
0.04 |
| Depression |
0 |
0.04 |
| Dysmenorrhea |
0 |
0.04 |
| Endocrine Society |
0 |
0.04 |
| Face |
0 |
0.04 |
| Fibroma |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Generics |
0 |
0.04 |
| Gonadotropin-Releasing Hormone (GnRH) Agonists |
0 |
0.04 |
| Headache |
0 |
0.04 |
| Hemorrhage |
0 |
0.04 |
| Hirsutism |
0 |
0.04 |
| Ligament |
0 |
0.04 |
| Menopausal Vasomotor Symptoms |
0 |
0.04 |
| Menstrual Disorder |
0 |
0.04 |
| Nausea |
0 |
0.04 |
| Patient Safety |
0 |
0.04 |
| Pituitary Gland |
0 |
0.04 |
| Scalp |
0 |
0.04 |
| Sleep |
0 |
0.04 |
| Steroids |
0 |
0.04 |
| Transdermal |
0 |
0.04 |
| Ultrasonography |
0 |
0.04 |